Heterogeneous distributions in clinical events preceding anticoagulant treatment nonpersistence in patients with venous thromboembolism stratified by active cancer: A nationwide cohort study

Heterogeneous distributions in clinical events preceding anticoagulant treatment nonpersistence in patients with venous thromboembolism stratified by active cancer: A nationwide cohort study

Abstract Background Nonpersistence in anticoagulation therapy is common and associated with undesirable clinical outcomes in patients with venous thromboembolism (VTE). Methods We investigated preceding clinical events of treatment nonpersistence (e.g., switching, discontinuing, or restarting) in VT...

Full description

Bibliographic Details
Main Authors:	Dongwon Yoon, Han Eol Jeong, Songhwa Choi, Daye Lee, Ju‐Young Shin, Soo‐Mee Bang
Format:	Article
Language:	English
Published:	Wiley 2023-11-01
Series:	Cancer Medicine
Subjects:	active cancer anticoagulant treatment clinical events nonpersistence venous thromboembolism
Online Access:	https://doi.org/10.1002/cam4.6626

Similar Items

Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
by: Dongwon Yoon, et al.
Published: (2023-09-01)

Optimal duration of anticoagulant therapy in patients with venous thromboembolism
by: Gualtiero Palareti
Published: (2018-09-01)

Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism
by: A. V. Rudakova
Published: (2015-11-01)

Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Real‐World Practice Mirrors Guideline Recommendations
by: Elizabeth Joyce, et al.
Published: (2022-11-01)

Patients with Cushing’s syndrome suffer from provoked venous thromboembolism and are anticoagulated in various patterns
by: Agata Hanna Bryk-Wiązania, et al.
Published: (2024-08-01)

Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy
by: Gary E. Raskob
Published: (2024-05-01)

Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes
by: Nichole E. Brunton, et al.
Published: (2021-05-01)

Bleeding and venous thromboembolism events in cancer patients taking direct oral anticoagulants vs. low molecular weight heparin
by: Frank A. Lattuca, et al.
Published: (2023-03-01)

The recent clinical trials on use of the novel direct oral anticoagulants in patients with venous thromboembolism: a review
by: Gualtiero Palareti
Published: (2014-10-01)

A Cross-sectional Study of the Assessment of Venous Thromboembolism Risk and Use of Anticoagulant Thromboprophylaxis
by: Emile Abimana, et al.
Published: (2022-03-01)

Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism
by: Brian J. Carney, et al.
Published: (2020-07-01)

The treatment of venous thromboembolism with new oral anticoagulants
by: Davide Imberti
Published: (2013-12-01)

The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment
by: К. V. Lobastov, et al.
Published: (2020-05-01)

Factor XI, a potential target for anticoagulation therapy for venous thromboembolism
by: Tingting Li, et al.
Published: (2022-10-01)

Newer oral anticoagulants in venous thromboembolism
by: Sunil Modi, et al.
Published: (2021-01-01)

Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden
by: Yanina Balabanova, et al.
Published: (2022-02-01)

Treatment and secondary prophylaxis of venous thromboembolism with direct oral anticoagulants in patients with severe hereditary thrombophilia
by: Pasquale Madonna, et al.
Published: (2021-03-01)

Persistence and nonpersistence as complementary models of identical quantum particles
by: Philip Goyal
Published: (2019-01-01)

Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis
by: Karlyn A. Martin, et al.
Published: (2020-10-01)

Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
by: Mette Søgaard, et al.
Published: (2019-03-01)

ANTICOAGULANT THERAPY OF VENOUS THROMBOEMBOLIC COMPLICATIONS: PROBLEMS AND PERSPECTIVES
by: N. M. Vorobieva, et al.
Published: (2015-03-01)

Recent advances in mechanism and anticoagulant therapy of venous thromboembolism in patients with non-dialysis chronic kidney disease
by: Jia-xin Wang, et al.
Published: (2024-09-01)

Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice
by: I. V. Zotova, et al.
Published: (2020-09-01)

Risk of Recurrent Venous Thromboembolism in Selected Subgroups of Men: A Danish Nationwide Cohort Study
by: Ida Ehlers Albertsen, et al.
Published: (2022-10-01)

Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
by: Cristiano Bortoluzzi, et al.
Published: (2022-10-01)

A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism
by: Gabrielle Sarlon-Bartoli, et al.
Published: (2023-12-01)

Venous thromboembolic complications
by: G. G. Khubulava, et al.
Published: (2019-02-01)

Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia
by: Evelien Krumb, et al.
Published: (2021-02-01)

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
by: Géraldine Poénou, et al.
Published: (2023-08-01)

Bleeding in women with venous thromboembolism during pregnancy: A systematic review of the literature
by: Camille Simard, et al.
Published: (2022-08-01)

Validation of the HAS-BLED scale for the assessment of bleeding risk in patients on anticoagulation therapy with a diagnosis of venous thromboembolic disease
by: Stephanie Ortiz-Gómez, et al.
Published: (2024-10-01)

Efficacy and safety of anticoagulants on venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
by: Weijie Fu, et al.
Published: (2025-01-01)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017-08-01)

FEATURES OF PROPHYLAXIS OF POSTOPERATIVE VENOUS THROMBOEMBOLISM IN ONCOLOGIC PATIENTS
by: I. I. Katelnitskyy, et al.
Published: (2014-12-01)

Contrasts in Glioblastoma—Venous Thromboembolism versus Bleeding Risk
by: Viktoria Muster, et al.
Published: (2021-06-01)

Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis
by: Zoe H. Tu, PharmD, et al.
Published: (2024-05-01)

Risk factors for Venous Thromboembolism and clinical outcomes in adults with sickle cell disease
by: Brittany Scarpato, et al.
Published: (2022-03-01)

EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON
by: V. I. Petrov, et al.
Published: (2016-12-01)

Physician perceptions and use of reduced‐dose direct oral anticoagulants for extended phase venous thromboembolism treatment
by: Danielle Groat, et al.
Published: (2022-05-01)

Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
by: Francesco Poletto, et al.
Published: (2022-03-01)